About this trial
Myotonic Dystrophy Type 1 (DM1) is a rare genetic neuromuscular condition that can affect multiple organs and varies widely in how it presents. DM1 is the most common form of adult-onset muscular dystrophy, with an estimated prevalence of approximately 1-5 per 10,000 people. In Spain, the condition shows notable regional differences, making it especially important to understand its characteristics within the population.
The aim of this study is to support a research initiative designed to better characterise DM1. We are developing a comprehensive national registry, collecting patient-reported information, clinical data and omics data that will improve our understanding of the disease and help identify individuals who may be eligible for clinical trials.
Eligibility criteria
Qualifiers
Confirmed diagnosis of Myotonic Dystrophy Type 1 (DM1) through genetic testing.
Disqualifiers
There are no exclusion criteria for the registry
Trial design
Treatments tested in this trial
- Patient Registry
Treatment groups
Locations
8Map coordinates are unavailable for these locations. Locations are shown below instead.
Sponsors and collaborators
Fundació Institut Germans Trias i Pujol
Lead sponsor
Instituto de Investigacion Sanitaria INCLIVA
Collaborator
Biobizkaia Health Research Institute
Collaborator
Biogipuzkoa Health Research Institute
Collaborator
Germans Trias i Pujol Hospital
Collaborator
Hospital Infanta Sofia
Collaborator
Hospital de Basurto
Collaborator
Hospital Donostia
Collaborator
Hospitales Universitarios Virgen del Rocío
Collaborator
Hospital Universitario Marqués de Valdecilla
Collaborator
Complejo Hospitalario Universitario de Albacete
Collaborator
Hospital Universitario La Fe
Collaborator
Hospital Univeritario Ntra. Sra. de la Candelaria
Collaborator